Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.77 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.70 |
| ▸ | METAP2 | P50579 | 2/20 | 0.64 |
| ▸ | CCR2 | P41597 | 3/20 | 0.57 |
| ▸ | CCR1 | P32246 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491987 | 0.90 | ALDH1A1 (0.81) | ALDH1A1KDM4ERCE1METAP2TP53 | |
| SCHEMBL31123669 | 0.88 | ALDH1A1 (0.79) | ALDH1A1KDM4ERCE1METAP2MEN1 | |
| SCHEMBL31681244 | 0.83 | KDM4E (0.71) | ALDH1A1KDM4ERCE1METAP2MEN1 | |
| SCHEMBL10249221 | 0.81 | ACLY (0.67) | ALDH1A1METAP2LMNA | |
| SCHEMBL491713 | 0.81 | ALDH1A1 (0.67) | ALDH1A1KDM4ETP53MEN1KMT2A | |
| SCHEMBL6713098 | 0.80 | KDM1A (0.68) | ALDH1A1METAP2CCR2CCR1 | |
| SCHEMBL492024 | 0.80 | ACLY (0.81) | ALDH1A1METAP2 | |
| SCHEMBL491833 | 0.78 | METAP2 (1.00) | ALDH1A1METAP2CCR2TP53KMT2A | |
| SCHEMBL5141365 | 0.78 | ALDH1A1 (0.64) | ALDH1A1KDM4ETP53MEN1KMT2A | |
| SCHEMBL164916 | 0.78 | LMNA (0.72) | ALDH1A1CCR2CCR1TP53MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2207541-B1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-10-29 | — | — | EP | disclosed |
| US-8541410-B2 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8518998-B2 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| CN-101815514-B | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI AVENTIS DEUTSCHLAND | 2012-05-09 | — | — | CN | disclosed |
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS DEUTSCHLAND GMBH | 2012-05-03 | — | — | US | disclosed |
| US-8106213-B2 | For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| CN-101815514-A | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SANOFI AVENTIS DEUTSCHLAND | 2010-08-25 | — | — | CN | disclosed |
| EP-2207541-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | Sanofi-Aventis Deutschland GmbH (DE) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009043495-A1 | USE OF SULFONYL-SUBSTITUTED 2-SULFONYLAMINOBENZOIC ACID N-PHENYLAMIDES IN THE TREATMENT OF PAIN | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-04-09 | — | — | WO | disclosed |
| WO-2004033419-A1 | SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030054433-A1 | Method for detecting oxidized forms of soluble guanylate cyclase and a method for screening for activators of soluble guanylate cyclase having oxidized heme iron | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-03-20 | — | — | US | disclosed |
| US-6500631-B1 | WHOSE HEME IRON IS IN THE TRIVALENT OXIDATION STATE, AND TO METHODS FOR FINDING CHEMICAL SUBSTANCES WHICH STIMULATE THE ACTIVITY OF A SOLUBLE GUANYLATE CYCLASE WHEN THE HEME IRON OF AT LEAST PART OF THIS SOLUBLE GUANYLATE CYCLASE IS OXIDIZED TO | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-31 | — | — | US | disclosed |
| EP-1218535-A2 | METHOD FOR THE DETECTION OF OXIDIZED FORMS OF SOLUBLE GUANYLATE CYCLASE | Aventis Pharma Deutschland GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMA DEUTSCHLAND GMBH | 2002-05-23 | — | — | US | disclosed |
| US-6335334-B1 | HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-01 | — | — | US | disclosed |
| CN-1308606-A | Sulfur-substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | AVENTIS PHARMACEUTICALS AG (DE) | 2001-08-15 | — | — | CN | disclosed |
| EP-1095016-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Aventis Pharma Deutschland GmbH (DE) | 2001-05-02 | — | — | EP | disclosed |
| WO-2001020023-A2 | METHOD FOR THE DETECTION OF OXIDIZED FORMS OF SOLUBLE GUANYLATE CYCLASE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000002851-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108573-A1 | SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | GUCY1A1, GUCY1B1, GUCY1A2 | ALDH1A1 457/4885KDM4E 3935/4885RCE1 847/4885 |
| US-20110021505-A1 | Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid N-phenylamides in the treatment of pain | SCN1A, SCN2A, CACNA1A | ALDH1A1 494/4885KDM4E 1745/4885RCE1 2451/4885 |
| US-20020061887-A1 | Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them | GUCY1A1, GUCY1B1, GUCY1A2 | ALDH1A1 860/4885KDM4E 4029/4885RCE1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.